Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
36.59 USD   +1.22%
11/30Zai Lab : to Present Interim Overall Survival Results for ZEJULA« (niraparib) from the Phase 3 NORA Study at the ESMO Virtual Plenary
PU
11/29Hopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab : Corporate Presentation

09/27/2022 | 08:41am EST

Building a Global Biopharma Leader

September 2022

Forward-Looking Statements

This presentation contains statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding our ability to advance our clinical pipeline and further demonstrate our commercial and discovery capabilities, expected milestones for our products and product candidates, and other statements containing words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this presentation and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward- looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) the effects of the coronavirus (COVID-19) pandemic, including any government actions or lockdown measures taken in response, on our business and general economic, regulatory and political conditions, (6) risks related to doing business in China, and (7) other factors discussed in our most recent annual and quarterly reports and other reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

Our SEC filings can be found on our website at www.zailaboratory.comand on the SEC's website at http://www.sec.gov.

This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities of Zai Lab Limited.

2

We Are On Track to Deliver 2022 Corporate Priorities in the Second Quarter

Achieved Key Regulatory

Milestones

  • Efgartigimod

China BLA acceptance

  • ZL-1102(IL-17)

Discussing trial protocol with the FDA for a global Ph2 program

Demonstrated Commercial

Excellence

  • ZEJULA

Revenue growth of 46% y-o-y and 15% q-o-q; on track to

become a PARP market

leader in ovarian cancer

Pipeline Continues to Demonstrate Best-in-class/First-in-class Potential

Positive data readouts since 2Q'22:

  • KarXT

Ph3 study in schizophrenia

  • Adagrasib

Ph2 registration-enabling study in NSCLC

  • CLN-081

Ph1/2a study in NSCLC

  • Repotrectinib

Ph1/2 registrational study in ROS1+ NSCLC

  • TTFields

Ph2 pilot study in GC

  • Efgartigimod

Ph3 study in ITP

  • ZEJULA

Subgroup analysis of Ph3 study in OC1

Capital Markets & Corporate

Governance Enhancements

Support Long-term Growth

  • Engagement of U.S. Auditor Subject to PCAOB Inspection

Zai believes we will comply with the audit requirements of the HFCAA for fiscal year 2022

  • Primary Listing & Stock Connect Inclusion in Hong Kong

Additional opportunity for eligible investors in mainland China to invest in Zai

  • COO Joins Zai

Josh Smiley joined as Chief

Operating Officer on August 1

Abbreviations: National Reimbursement Drug List (NRDL), year-over-year(y-o-y),quarter-over-quarter(q-o-q),non-small-cell lung cancer (NSCLC), gastric cancer (GC), primary immune thrombocytopenia (ITP), ovarian cancer (OC),

3 Holding Foreign Companies Accountable Act (HFCAA).

Notes: (1) A new prespecified subgroup analysis from the Ph3 PRIME study for niraparib in patients in China with ovarian cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Who We Are

Biotech mindset + Pharma quality + Zai Lab speed + Global talent

Leader in the 2nd-largest and a fast-growing pharma market with an unmatched portfolio

Bringing the best medicines to China today and to the world tomorrow Leveraging our strength in China to become a global biopharma leader

Diversified Commercial

Portfolio

2025…

Preferred

Integrated

Biopharma

Partner in China

2021

2017

Founded 2014

4

Differentiated Strategic Positioning and Financial Visibility

DEEP PIPELINE WITH CLEAR DIFFERENTIATION

De-risked portfolio addresses large unmet needs with breadth of modalities and disease area strongholds

SCIENCE-DRIVEN R&D WITH PROVEN GLOBAL CLINICAL DEVELOPMENT EXPERTISE

Focused and efficient R&D strategy delivering a pipeline with global rights in 5 years, with assets reaching proof-of-concept while adding global talent and capabilities

FULLY INTEGRATED PLATFORM FROM PARTNER OF CHOICE TO COMMERCIAL CAPABILITIES

Flywheel effect creating a virtuous cycle, quickly bringing innovative best-in-class/first-in-class assets to China and beyond

FINANCIAL STRENGTH, VISIBILITY AND CAPITAL EFFICIENCY

Continue to grow and execute with Zai Speed and Quality. Strong balance sheet (with a cash position of $1.26 billion as of June 30, 2022), commercial execution and productivity provide multi- year runway without impacting generational growth opportunity

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Zai Lab Ltd. published this content on 27 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 September 2022 12:40:03 UTC.


ę Publicnow 2022
All news about ZAI LAB LIMITED
11/30Zai Lab : to Present Interim Overall Survival Results for ZEJULA« (niraparib) from the Pha..
PU
11/29Hopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rat..
MT
11/17Asian Equities Diverge From US Markets, Climb in Thursday Trading
MT
11/15Zai Lab Grants American Depositary Shares
MT
11/11Asian ADRs Surge Higher in Friday Trading as China Eases COVID-19 Restrictions
MT
11/11Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating
MT
11/10Asian ADRs Soar in Thursday Trading Following US Inflation Data
MT
11/10Transcript : Zai Lab Limited, Q3 2022 Earnings Call, Nov 10, 2022
CI
11/09Zai Lab's Q3 Net Loss Widens
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 215 M - -
Net income 2022 -464 M - -
Net cash 2022 967 M - -
P/E ratio 2022 -7,02x
Yield 2022 -
Capitalization 3 512 M 3 512 M -
EV / Sales 2022 11,8x
EV / Sales 2023 6,40x
Nbr of Employees 1 951
Free-Float 97,4%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 36,59 $
Average target price 82,53 $
Spread / Average Target 126%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Peter Huang Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-41.78%3 512
CSL LIMITED3.84%98 736
SAMSUNG BIOLOGICS CO.,LTD.-3.65%47 474
BIOGEN INC.24.58%43 042
WUXI BIOLOGICS (CAYMAN) INC.-44.03%28 080
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.50%20 307